MedTrace Logo

HD11 for Intermediate Stages

NCT00264953 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1395

Last updated 2011-08-04

No results posted yet for this study

Summary

This study is designed to (1) compare the efficacy of the BEACOPP regimen with that of ABVD as a 4-cycle chemotherapy combined with an involved field irradiation and (2) to define the optimum radiation dose comparing of 30 to 20 Gy in the same context.

Conditions

  • Hodgkin´s Lymphoma

Interventions

DRUG

Adriamycin

DRUG

Bleomycin

DRUG

Vinblastine

DRUG

DTIC

DRUG

Etoposide

DRUG

Procarbazine

DRUG

Prednisone

DRUG

Vincristine

RADIATION

radiation therapy

20 or 30Gy IF-RT

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Volker Diehl, Prof. · University of Cologne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-05-31
Primary Completion
2003-01-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00264953 on ClinicalTrials.gov